戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ed Jagged1 using osteoblast-specific Jagged1 transgenic mouse model.
2 n-target/off-tumor toxicity in a human CD147 transgenic mouse model.
3 stemic anaphylaxis in human FcepsilonRIalpha transgenic mouse model.
4 ase (SCD) in a NRF2 knockout (SCD/NRF2(-/-)) transgenic mouse model.
5 apoptosis mediated by the p53 pathway in our transgenic mouse model.
6  cells, using a unique T cell receptor (TCR) transgenic mouse model.
7 impaired decidualization in both women and a transgenic mouse model.
8 progression of retinal pathology in a PD/DLB transgenic mouse model.
9 was further demonstrated in vivo using a CLL transgenic mouse model.
10  different EAE models, including the 2D2 TCR-transgenic mouse model.
11 and elicit functional improvement in an aged transgenic mouse model.
12 ing breast cancer progression in a MMTV-PyMT transgenic mouse model.
13 etworks and inhibited tumor progression in a transgenic mouse model.
14 U2AF1 mutation using a doxycycline-inducible transgenic mouse model.
15 epox/ectromelia virus (ECTV)-infection, B7.2 transgenic mouse model.
16  intracerebroventricular infusion in an aged transgenic mouse model.
17 eractions to induce leukemia in the Emu-TCL1 transgenic mouse model.
18 anied by visual deficits in a tie2-TNF-alpha transgenic mouse model.
19 on of USP6 enhances learning and memory in a transgenic mouse model.
20  modifier identified by the screen-in an APP transgenic mouse model.
21 with cognitive improvements in an AD APP/PS1 transgenic mouse model.
22 attenuate acute colitis in a humanized IL-26 transgenic mouse model.
23 tau protein aggregation both in vitro and in transgenic mouse models.
24 ed this hypothesis, using highly replicative transgenic mouse models.
25  using tetracycline- and tamoxifen-inducible transgenic mouse models.
26  of Interleukin (IL)-10 in the brains of APP transgenic mouse models.
27 ain and in Abeta precursor protein (AbetaPP) transgenic mouse models.
28 ical alternative to conditional knockout and transgenic mouse models.
29 etic screen were fulfilled in our studies of transgenic mouse models.
30 kout mouse lines in addition to the existing transgenic mouse models.
31 ty and the formation of amyloid plaques in a transgenic mouse model (5xFAD) of early amyloid depositi
32                          We showed that in a transgenic mouse model, activation of the UPR in early d
33 diomyocyte-specific, doxycycline-regulatable transgenic mouse model aggravated cardiac hypertrophy, f
34  in human tau overexpressing line 66 mice, a transgenic mouse model akin to genetic variants of front
35 riggers, could prevent disease symptoms in a transgenic mouse model and a knockin mouse model of the
36 urther generated a corresponding betaH1-eGFP transgenic mouse model and demonstrated the presence of
37 t manner, and is strongly activated in 5XFAD transgenic mouse model and human AD brains.
38  interstitial fluid (ISF) and CSF from an AD transgenic mouse model and postmortem ventricular and an
39                                Here, using a transgenic mouse model and primary cell cultures along w
40   We generated a cardiomyocyte-targeted Nox2-transgenic mouse model and studied the effects of in viv
41    Using various inducible and site-specific transgenic mouse models and pharmacological validation e
42 overcome these limitations, we combined here transgenic mouse models and proteomic analyses in order
43  tissue; CC cell xenografts; a p53-deficient transgenic mouse model; and a non-transgenic, chemically
44 s decreased in the brains of AD patients and transgenic mouse model, as well as Abeta-treated cells.
45         This work describes the first double transgenic mouse model bearing both human FcRn and HSA g
46 dividual B cell clones from two distinct BCR transgenic mouse models but is dispensable for all of th
47                          Studying the EPR in transgenic mouse models can define exact mechanisms of t
48 fects of soticlestat were characterized in a transgenic mouse model carrying mutated human amyloid pr
49                                        Using transgenic mouse models, cell line-based functional stud
50 sphoribosyltransferase locus, we generated a transgenic mouse model containing the human renin (hREN)
51 st time Pcdh10 up-regulation in tissues from transgenic mouse models, cultured Schwann cells, and hum
52 tution of bone marrow cells into a TGF-alpha transgenic mouse model demonstrated that fibrocytes do n
53                                 In a somatic transgenic mouse model, depletion of Bcl6 inhibits the p
54                               We generated a transgenic mouse model (EAAT3(glo)) to achieve condition
55 ire breadth to a non-self-antigen, a TCRbeta transgenic mouse model (EF4.1) expressing a limited, yet
56                                      Using a transgenic mouse model engineered so that lactogenic hor
57  first report of a newly generated humanized transgenic mouse model engineered to express human NRG1-
58                     Here, we present a novel transgenic mouse model expressing a hepatocyte-specific
59                  In this study, we present a transgenic mouse model expressing a photoactivated adeny
60                                         In a transgenic mouse model expressing a VEGF-C/D trap and di
61                                         This transgenic mouse model expressing an ERalpha folding-bio
62              In the present study, the first transgenic mouse model expressing dog prion protein (PrP
63                                   Boosting a transgenic mouse model expressing germline VRC01 heavy c
64 c alleviated S. pyogenes-induced sepsis in a transgenic mouse model expressing human FH (S. pyogenes
65                            Here we show in a transgenic mouse model expressing mutant human tau predo
66 er mammals and humans, but not in rodents, a transgenic mouse model expressing the complete human MOG
67                               We generated a transgenic mouse model expressing the E7 oncoprotein of
68                                              Transgenic mouse models expressing mutant superoxide dis
69 anamide, was investigated in the brain of AD transgenic mouse models (FAD) on an APOE4 or APOE3 genet
70 ntration in vivo, we developed a conditional transgenic mouse model (Flpo/Frt system) expressing bioa
71                                     In a new transgenic mouse model fluorescent reporter protein expr
72  blockade in the K14cre;Cdh1(F/F);Trp53(F/F) transgenic mouse model for breast cancer stimulates intr
73                                            A transgenic mouse model for congenital stationary night b
74 he advantages and limitations of the HLA-DR4 transgenic mouse model for evaluating human C. trachomat
75 id leukemia (AML), we generated an inducible transgenic mouse model for MLL-AF9-driven leukemia.
76                                      Using a transgenic mouse model for the sonic hedgehog (Shh) subg
77                                        Using transgenic mouse models for cell-specific HIF expression
78                     Using recently developed transgenic mouse models for LIN28B and let-7g, we demons
79 t composition in the skin, we have generated transgenic mouse models for tamoxifen-inducible de novo
80 ) and previously undescribed (G2-Gata4(Cre)) transgenic mouse models for the study of coronary vascul
81 ue expression in Tg32, a human FcRn knock-in transgenic mouse model, for which a strong correlation o
82                              Using the TRAMP transgenic mouse model, glipizide, a widely used drug fo
83  of IR-induced DSBs to GBM development using transgenic mouse models harboring brain-targeted deletio
84 exanucleotide repeat expansion in ALS/FTD, a transgenic mouse model has remained elusive.
85 f the problem with AD drug discovery is that transgenic mouse models have been poor predictors of pot
86 n the majority of Rett Syndrome (RTT) cases, transgenic mouse models have played a critical role in o
87                              Biophysical and transgenic mouse models have provided insight into the m
88 ine phosphatases Shp1 and Shp2, knockout and transgenic mouse models have revealed distinct phenotype
89 el, Hi-Myc mice, with a liver-specific IGF-1 transgenic mouse model (HIT) to increase their circulati
90                                      Using a transgenic mouse model in which FlnA is selectively depl
91 severative behaviors, we characterized a new transgenic mouse model in which inducible ablation of SC
92 o address this gap, we developed a new IL-33 transgenic mouse model in which overexpression of full-l
93 cted CC, a toxin-driven model in rats, and a transgenic mouse model in which p53 deletion is targeted
94                              We used a novel transgenic mouse model in which the human diphtheria tox
95 V-induced skin carcinogenesis, we utilized a transgenic mouse model in which the keratin 14 promoter
96                    Here, we use an inducible transgenic mouse model in which the pro-apoptotic gene B
97                      We have developed a new transgenic mouse model in which we can induce expression
98                          Here, we describe a transgenic mouse model in which we expressed a mitochond
99          We studied autoresuscitation in two transgenic mouse models in which exocytic neurotransmitt
100  injury pharmacologically and genetically in transgenic mouse models in which microglia and systemic
101                                 Studies in a transgenic mouse model indicated that these compounds co
102 ation and improves survival in a calcineurin transgenic mouse model, indicating that COUP-TFII may se
103                                     This hAS transgenic mouse model is therefore an ideal animal mode
104 fic dominant-negative (DN) TCF7L2 (TCF7L2DN) transgenic mouse model LTCFDN.
105 ow for the first time that, unlike other tau transgenic mouse models, minimal expression of a human d
106                         Here, we developed a transgenic mouse model (NRG1-IV/NSE-tTA) in which human
107 ivery in both wild type mice and the NSG-PiZ transgenic mouse model of AAT deficiency.
108 uppress the Alzheimer's-like phenotypes in a transgenic mouse model of Abeta deposition.
109 es over the course of neurodegeneration in a transgenic mouse model of AD (3xTg-AD).
110 to investigate brain copper trafficking in a transgenic mouse model of AD by PET imaging with (64)Cu,
111 that reducing endogenous alpha-syn in an APP transgenic mouse model of AD prevented the degeneration
112  of Western diet (WD) on female EFAD mice, a transgenic mouse model of AD that includes human APOE al
113                                         In a transgenic mouse model of AD, aducanumab is shown to ent
114                                    In an APP transgenic mouse model of AD-like amyloid pathology we f
115  we confirm these results in vivo by using a transgenic mouse model of AD.
116 which demonstrated oral activity in a triple-transgenic mouse model of AD.
117 d precursor protein (APP)/presenilin 1 (PS1) transgenic mouse model of AD.
118 hemorrhage, ameliorates AD pathogenesis in a transgenic mouse model of AD.
119  synapse loss and for learning deficits in a transgenic mouse model of AD.
120     Mechanistic analysis was undertaken in a transgenic mouse model of ALS, where we find similar mar
121 genous alpha-synuclein (alpha-syn) in an APP transgenic mouse model of Alzheimer's disease (AD) preve
122 S)-induced microglia activation in vivo in a transgenic mouse model of Alzheimer's disease (APP/PS1)
123 subsequent fluorescent amyloid staining in a transgenic mouse model of Alzheimer's disease (tgSwe).
124 el of amyloid beta induced memory loss and a transgenic mouse model of Alzheimer's disease.
125 d in affected neuronal tissues from a TDP-43 transgenic mouse model of amyotrophic lateral sclerosis
126                                         In a transgenic mouse model of androgen-responsive prostate c
127                                            A transgenic mouse model of Anks1b haploinsufficiency reca
128  we report the characterization of the first transgenic mouse model of ARVC5.
129 are antipruritic against acute itch and in a transgenic mouse model of atopic dermatitis produced by
130 D8+ T cells are implicated as effectors in a transgenic mouse model of autoimmune GFAP meningoencepha
131                                 In an S100A7 transgenic mouse model of breast cancer (mS100a7a15 mice
132  of CaSR-PTHrP interactions in the MMTV-PymT transgenic mouse model of breast cancer and in human bre
133                             In the MMTV-PyMT transgenic mouse model of breast cancer and in oral squa
134 W)-MRI in the polyoma virus middle T antigen transgenic mouse model of breast cancer.
135 results in suppression of tumour growth in a transgenic mouse model of breast cancer.
136                                         In a transgenic mouse model of cancer, the B7-H3-targeted ult
137 igated the impact of gammadelta T cells in a transgenic mouse model of carcinogenesis induced by HPV1
138                          METHODS AND Using a transgenic mouse model of cardiac lipotoxicity overexpre
139 th plaque deposition and neuronal death in a transgenic mouse model of cerebral beta-amyloidosis.
140 on of HBV-specific CD8 T cell responses in a transgenic mouse model of chronic HBV infection.
141                                    We used a transgenic mouse model of chronic lung disease induced b
142                               We generated a transgenic mouse model of CMT2A that developed severe ea
143  vivo relevance of this pathway in our IL-15 transgenic mouse model of CTCL by showing that interfere
144                 In this study we have used a transgenic mouse model of dementia (rTg4510 mice), which
145 logical approaches, we have shown that, in a transgenic mouse model of dementia, the functional prope
146                              Here, we used a transgenic mouse model of diabetes to probe the gene exp
147 GMP signaling.SIGNIFICANCE STATEMENT In DYT1 transgenic mouse model of dystonia, PDE10A, a key enzyme
148 ion and cardiac metabolism are affected in a transgenic mouse model of enhanced cardiac glycolysis (G
149                                  In the PS19 transgenic mouse model of FTD, administration of salsala
150 nt stem cells into the anterior chamber of a transgenic mouse model of glaucoma.
151                        Hepatitis B X protein transgenic mouse model of HCC recapitulates this paradig
152                                 We created a transgenic mouse model of HCDD using targeted insertion
153  and improves phenotype and survival in R6/2 transgenic mouse model of HD.
154 ivity and local field potentials in the R6/2 transgenic mouse model of HD.
155 ilin degradation and rescued phenotypes in a transgenic mouse model of hereditary primary open-angle
156                             In the K14-HPV16 transgenic mouse model of HPV-driven neoplasms, direct c
157                         Using an established transgenic mouse model of HPV16 E7-induced HNSCC, we dem
158    Here we report novel findings in the R6/2 transgenic mouse model of Huntington's disease (HD) by d
159 duced in striatal output neurons of the R6/2 transgenic mouse model of Huntington's disease, at an ag
160 dependent microvascular disease is seen in a transgenic mouse model of IFN toxicity.
161 ing required Bcl2-mediated autophagy using a transgenic mouse model of impaired inducible autophagy (
162      Using a human islet amyloid polypeptide transgenic mouse model of islet amyloidosis, we show ARC
163                 In this study, we describe a transgenic mouse model of KRAS-driven lung adenocarcinom
164                        In a syngeneic HLA-A2-transgenic mouse model of large established tumors, we f
165 xoguanine DNA glycosylase (OGG1) in the PyMT transgenic mouse model of mammary tumorigenesis.
166 ymal transition and metastasis, an MMTV-PyMT transgenic mouse model of mammary tumour progression and
167      Here, we further characterized a lethal transgenic mouse model of MERS-CoV infection and disease
168 teolipid protein alpha-syn (PLP-SYN) mice, a transgenic mouse model of MSA.
169 non of reduced OEMVs was again observed in a transgenic mouse model of multiple system atrophy and in
170 patients and reduced IGF-1 brain levels in a transgenic mouse model of multiple system atrophy.
171                    Here, we report that in a transgenic mouse model of MYC-induced T-cell leukemia, M
172                          Using a "humanized" transgenic mouse model of nasal colonization, we took a
173         (iii) Immunization of an HLA-A*02:01 transgenic mouse model of ocular herpes with "ASYMP" CD8
174                                      Using a transgenic mouse model of Parkinson's disease (PD) that
175 res, as well as in transgenic mice and a non-transgenic mouse model of PD.
176  our results show in an aggressively growing transgenic mouse model of PDAC that the coordinated acti
177                    We previously generated a transgenic mouse model of PPFP thyroid carcinoma and sho
178 se hypotheses were tested using cells from a transgenic mouse model of prostate cancer infected with
179 nic adenocarcinoma of mouse prostate (TRAMP) transgenic mouse model of prostate cancer.
180                                    We used a transgenic mouse model of pulmonary arterial hypertensio
181                                         In a transgenic mouse model of resectable PDAC, we investigat
182                We validated this method in a transgenic mouse model of selective podocyte depletion,
183  and autoimmune kidney disease in the Tlr7.1 transgenic mouse model of SLE.
184  mtDNA genomes on the background of the PyMT transgenic mouse model of spontaneous mammary carcinoma.
185 al deletion of Ldb1 in thymocytes in an Lmo2 transgenic mouse model of T-ALL.
186 emporal structure of SWRs was disrupted in a transgenic mouse model of tauopathy (one of the major ha
187                      Moreover, in a relevant transgenic mouse model of tauopathy, down-regulation of
188 s, neuroinflammation, neurodegeneration in a transgenic mouse model of tauopathy.
189 endritic metaplasticity is dysregulated in a transgenic mouse model of the disease, either before or
190                          We have developed a transgenic mouse model of Type 1 Diabetes (T1D) in which
191 odegeneration remain unclear, we generated a transgenic mouse model of UCH-L1 deficiency.
192                  Here we introduce the first transgenic mouse model of uveal melanoma, which develops
193 To test this, we used a previously described transgenic mouse model of wound-induced skin tumorigenes
194 Vs, and synthesize preclinical findings from transgenic mouse models of 16p11.2 CNVs.
195           Lesions of the LC in amyloid-based transgenic mouse models of AD exacerbate Abeta pathology
196 ortem brain tissue samples from AD patients, transgenic mouse models of AD, and neuronal cells were u
197  was activated in reactive astrocytes in two transgenic mouse models of Alzheimer's disease and in a
198 s amyloid aggregation in cells, worms and in transgenic mouse models of Alzheimer's disease.
199 ulates amyloidosis and memory impairments in transgenic mouse models of Alzheimer's disease.
200 tigated behavioral and pathologic changes in transgenic mouse models of amyotrophic lateral sclerosis
201 29 would attenuate pulmonary hypertension in transgenic mouse models of Bmpr2 mutation.
202 derived tumor xenograft (PDX) and MYC-driven transgenic mouse models of breast cancer by inhibiting t
203 a result of tumor formation in two different transgenic mouse models of cancer (RIP1-Tag2 model of in
204                                        Using transgenic mouse models of cancer, we found that express
205                                     Existing transgenic mouse models of DYT11 exhibit only mild motor
206                         Here we show that in transgenic mouse models of early AD, direct optogenetic
207 odeled acquired resistance to osimertinib in transgenic mouse models of EGFR(L858R) -induced lung ade
208 olysis events observed in vivo, we generated transgenic mouse models of HD representing five distinct
209 Here, we use bacterial artificial chromosome transgenic mouse models of LRRK2 to explore potential no
210  breast cancer metastasis in two conditional transgenic mouse models of PyMT-induced breast cancer.
211 emonstrate a significant analgesic effect in transgenic mouse models of SCD and cancer as well as com
212 ion of SMN protein in human cells and in two transgenic mouse models of SMA.
213 oters, and disruption of endogenous genes in transgenic mouse models of tauopathy make it difficult t
214  Disappointingly, the initial enthusiasm for transgenic mouse models of the disease has not been foll
215 s mutant SOD1 expression is recapitulated in transgenic mouse models of the disease.
216  VIPR2 bacterial artificial chromosome (BAC) transgenic mouse models of VIPR2 CNV.
217 t the generation of Alzheimer's disease (AD) transgenic mouse models on a panel of 28 background stra
218        To address this gap, we developed two transgenic mouse models on the C57BL/6 background by ove
219                      In the MMTV-Delta16HER2 transgenic mouse model, oncogene transformation resulted
220 in DIV7 cortical cultures of either from E18 transgenic mouse model or from rat E18 embryos that were
221              We therefore generated a double-transgenic mouse model overexpressing both human heparan
222                                 Here, we use transgenic mouse models producing CAA mutants (Tg-SwDI)
223       Aha1 overexpression in the rTg4510 tau transgenic mouse model promoted insoluble and oligomeric
224 l cognitive assessment (water maze) in an AD transgenic mouse model (PS2APP) from 8 to 13 mo of age,
225  in LTP/LTD magnitude seen across ages in AD transgenic mouse models reflect the inability to undergo
226 nfection model and a lethal model makes this transgenic mouse model relevant for advancing MERS resea
227 udied the contribution of REST to MB using a transgenic mouse model (RESTTG ) wherein conditional Neu
228 ified a beneficial taxonomic repertoire in a transgenic mouse model (RIP140mvarphiKD) which resists t
229                      The PRMT overexpression transgenic mouse models should encourage and facilitate
230                                              Transgenic mouse models showed that norepinephrine dysre
231                    Here we report that, in a transgenic mouse model simulating the duplication condit
232 f Tau and neurofilament (NF) proteins in ALS transgenic mouse model (SOD1G37R).
233                                Evidence from transgenic mouse models suggests mutant forms of FUS exe
234                                   The use of transgenic mouse models targeting either whole ERalpha i
235 riven tumor progression, we generated triple-transgenic mouse model (tetO-EGFR(L858R); CCSP-rtTA; Mal
236 e therapeutic profile of CpG ODN in a triple transgenic mouse model, Tg-SwDI, with abundant vascular
237 o brain slice culture model for CWD, using a transgenic mouse model (Tg12) that expresses the elk (Ce
238                               We developed a transgenic mouse model that allows for lung-specific exp
239                               We developed a transgenic mouse model that constitutively expresses a f
240   Previous studies described a TDP-43(A315T) transgenic mouse model that develops progressive motor d
241      In the current studies, we identified a transgenic mouse model that exhibited a dysplastic coron
242 on in vivo, we generated and characterized a transgenic mouse model that expresses a non-glycosylated
243                               We developed a transgenic mouse model that expresses cone PDE6 in rods
244             Here, we have generated a double-transgenic mouse model that expresses human CD1b and CD1
245                                          Our transgenic mouse model that expresses LacZ reporter unde
246                                 We created a transgenic mouse model that expresses the pH-dependent f
247                                      Using a transgenic mouse model that inducibly expresses Dkk1 in
248                  Using a powerful, inducible transgenic mouse model that overexpresses miR-155 and de
249 g electrophysiology, cellular markers, and a transgenic mouse model that specifically labels GABA cel
250          Here, we show through a conditional transgenic mouse model that the MYC oncogene, but not th
251               Here, we provide evidence from transgenic mouse models that Crebbp deletion results in
252  Here, we used the Vav1 promoter to generate transgenic mouse models that expressed either human STAT
253                  To this end, we created two transgenic mouse models; the iMS-Nrf2(flox/flox) and iMS
254                                        Using transgenic mouse models, these results demonstrate that
255                               We generated a transgenic mouse model (TNF-alpha(glo)) that could be us
256                         Here we used a novel transgenic mouse model to compare the spatial distributi
257  In this issue of the JCI, Pham et al. use a transgenic mouse model to demonstrate that STAT5BN642H i
258 gionally restricted and temporally regulated transgenic mouse model to investigate the behavioral, mo
259                        We developed a triple-transgenic mouse model to map the fate of NG2(+)CD146(+)
260                                    We used a transgenic mouse model to show that the loss of presenta
261       This study used a cardiac-specific VCP transgenic mouse model to understand the transcriptomic
262 s neuron population, and employed additional transgenic mouse models to assess the role of one specif
263                      We utilized knockin and transgenic mouse models to evaluate the structural, func
264 ell type-specific loss- and gain-of-function transgenic mouse models to investigate the physiologic r
265                 Despite the extensive use of transgenic mouse models to investigate the propagation o
266                             The authors used transgenic mouse models to show that claudin-2 deficienc
267               The authors generated a double-transgenic mouse model, tTAxalphaMHCR403Q, in which expr
268 eloped bacterial artificial chromosome (BAC)-transgenic mouse model, we demonstrate that Lgr5 express
269 d precursor protein (APP)/presenilin 1 (PS1) transgenic mouse model, we found that inhibition of RIPK
270                                    Using our transgenic mouse model, we found that tetherin expressio
271 imeric cell-cell fusion assays, and a Sema3a transgenic mouse model, we identify Sema3a-Nrp1 signalin
272                      Using an IL-27 reporter transgenic mouse model, we show in this study that conve
273                                   Here, in a transgenic mouse model, we show that deletion of the gen
274          Here, using a tissue-specific miRNA transgenic mouse model, we show that interaction between
275                 Using the corresponding Plp1 transgenic mouse model, we then tested the capacity of t
276                                        Using transgenic mouse models, we demonstrate that lymphatic e
277                               Using targeted transgenic mouse models, we found that Vegfa is expresse
278                                        Using transgenic mouse models, we investigated the effect of S
279                                        Using transgenic mouse models, we show that B-cell-specific co
280 y and cognition in novel genetically matched transgenic mouse models, we surprisingly found that nonm
281       METHODS AND To address the question, 2 transgenic mouse models were generated: a phospho-mimeti
282                   To address this, we used a transgenic mouse model where Lamin B1 overexpression is
283                       Herein, we use a novel transgenic mouse model, where doxycycline-induced overex
284                 We turned to the DO11.10 TCR transgenic mouse model, where OVA is recognized in the c
285                We generated an autochthonous transgenic mouse model whereby conditional expression of
286 ectrophysiological recordings in the rTg4510 transgenic mouse model, which overexpresses a mutant for
287                   This further-characterized transgenic mouse model will be useful for advancing MERS
288 ediated skin cancer by interbreeding an HPV8 transgenic mouse model with a conditional disruption of
289 of TRAF3IP2 in heart disease, we generated a transgenic mouse model with cardiomyocyte-specific TRAF3
290 ere, we report the generation of a claudin-1 transgenic mouse model with doxycycline-inducible transg
291                                            A transgenic mouse model with elevated skeletal muscle 2-d
292 s phenomenon, we have developed an inducible transgenic mouse model with expression of the most commo
293 p52 expression in vivo, we generated a novel transgenic mouse model with inducible expression of p52
294 e, we studied retroviral susceptibility in a transgenic mouse model with lifelong innate immune syste
295                      In this study, we use a transgenic mouse model with T cells specific for the mer
296             We accordingly generated a novel transgenic mouse model with this EGFP expression vector
297 ional effects of TMPRSS2:ERG expression in a transgenic mouse model with those of ERG knockdown in a
298 er-induced choroidal neovascularization, and transgenic mouse models with deficient or spontaneous re
299                                              Transgenic mouse models with human monogenic-migraine-sy
300           Employing skeletal muscle-specific transgenic mouse models with unbiased-omic approaches, w

 
Page Top